Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Total Current Liabilities (2021 - 2025)

Goldenwell Biotech's Total Current Liabilities history spans 4 years, with the latest figure at $39360.0 for Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $39360.0; the TTM value through Sep 2025 reached $39360.0, changed N/A, while the annual FY2024 figure was $1860.0, N/A changed from the prior year.
  • Total Current Liabilities reached $39360.0 in Q3 2025 per GWLL's latest filing, down from $64360.0 in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $159266.0 in Q4 2021 to a low of $1860.0 in Q4 2024.
  • Average Total Current Liabilities over 4 years is $61648.8, with a median of $39856.0 recorded in 2022.
  • The largest YoY upside for Total Current Liabilities was 76.88% in 2022 against a maximum downside of 76.88% in 2022.
  • A 4-year view of Total Current Liabilities shows it stood at $159266.0 in 2021, then tumbled by 81.71% to $29126.0 in 2022, then tumbled by 93.61% to $1860.0 in 2024, then surged by 2016.13% to $39360.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Total Current Liabilities are $39360.0 (Q3 2025), $64360.0 (Q2 2025), and $1860.0 (Q4 2024).